Collegium Pharmaceutical, Inc.
COLL
$27.76
$0.712.63%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 14.22% | 9.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.22% | 9.65% | |||
| Cost of Revenue | 18.71% | 2.26% | |||
| Gross Profit | 13.56% | 10.83% | |||
| SG&A Expenses | 39.41% | -2.92% | |||
| Depreciation & Amortization | 35.96% | 18.21% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 33.95% | 5.59% | |||
| Operating Income | -22.16% | 18.02% | |||
| Income Before Tax | 10.84% | -46.45% | |||
| Income Tax Expenses | -24.21% | -34.20% | |||
| Earnings from Continuing Operations | 34.29% | -52.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 34.29% | -52.39% | |||
| EBIT | -22.16% | 18.02% | |||
| EBITDA | 2.40% | 17.89% | |||
| EPS Basic | 35.04% | -52.13% | |||
| Normalized Basic EPS | -44.03% | 13.36% | |||
| EPS Diluted | 30.78% | -48.73% | |||
| Normalized Diluted EPS | -44.29% | 13.39% | |||
| Average Basic Shares Outstanding | -0.56% | -0.53% | |||
| Average Diluted Shares Outstanding | -0.13% | -0.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||